巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2021-05-01
2021-08-26
2021-11-17
2023-02-15
2021-11-12
2021-10-19
2021-08-30
2023-02-28
2021-12-19
2021-10-06
2021-12-13
2022-02-21
